TrialLancet (London, England)2015

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Frederick J Raal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.